Skip to main content
Top
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Metastasis | Research article

Comparative transcriptome analysis of matched primary and distant metastatic ovarian carcinoma

Authors: H. Sallinen, S. Janhonen, P. Pölönen, H. Niskanen, O. H. Liu, A. Kivelä, J. M. Hartikainen, M. Anttila, M. Heinäniemi, S. Ylä-Herttuala, M. U. Kaikkonen

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

High grade serous ovarian carcinoma (HGSOC) is the most common subtype of epithelial ovarian cancers (EOC) with poor prognosis. In most cases EOC is widely disseminated at the time of diagnosis. Despite the optimal cytoreductive surgery and chemotherapy most patients develop chemoresistance, and the 5-year overall survival being only 25–35%.

Methods

Here we analyzed the gene expression profiles of 10 primary HGSOC tumors and 10 related omental metastases using RNA sequencing and identified 100 differentially expressed genes.

Results

The differentially expressed genes were associated with decreased embryogenesis and vasculogenesis and increased cellular proliferation and organismal death. Top upstream regulators responsible for this gene signature were NR5A1, GATA4, FOXL2, TP53 and BMP7. A subset of these genes were highly expressed in the ovarian cancer among the cancer transcriptomes of The Cancer Genome Atlas. Importantly, the metastatic gene signature was suggestive of poor survival in TCGA data based on gene enrichment analysis.

Conclusion

By comparing the gene expression profiles of primary HGSOC tumors and their matched metastasis, we provide evidence that a signature of 100 genes is able to separate these two sample types and potentially predict patient survival. Our study identifies functional categories of genes and transcription factors that could play important roles in promoting metastases and serve as markers for cancer prognosis.
Appendix
Available only for authorised users
Literature
6.
go back to reference Lancaster J, Dressman H, Clarke J, Sayer R, Martino M, Cragun J, et al. Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. Int J Gynecol Cancer 2006;16:1733–1745. Available from: http://ovidsp.ovid.com/ovidweb.cgi? T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00009577–200609000-00002. Lancaster J, Dressman H, Clarke J, Sayer R, Martino M, Cragun J, et al. Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. Int J Gynecol Cancer 2006;16:1733–1745. Available from: http://​ovidsp.​ovid.​com/​ovidweb.​cgi?​ T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00009577–200609000-00002.
38.
go back to reference Wang C, Armasu SM, Kalli KR, Maurer MJ, Heinzen EP, Keeney GL, et al. Pooled clustering of high-grade serous ovarian cancer gene expression leads to novel consensus subtypes associated with survival and surgical outcomes. Clinical Cancer research : an official journal of the American Association for Cancer Research 2017;23:4077-4085. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28280090.CrossRef Wang C, Armasu SM, Kalli KR, Maurer MJ, Heinzen EP, Keeney GL, et al. Pooled clustering of high-grade serous ovarian cancer gene expression leads to novel consensus subtypes associated with survival and surgical outcomes. Clinical Cancer research : an official journal of the American Association for Cancer Research 2017;23:4077-4085. Available from: https://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​28280090.CrossRef
Metadata
Title
Comparative transcriptome analysis of matched primary and distant metastatic ovarian carcinoma
Authors
H. Sallinen
S. Janhonen
P. Pölönen
H. Niskanen
O. H. Liu
A. Kivelä
J. M. Hartikainen
M. Anttila
M. Heinäniemi
S. Ylä-Herttuala
M. U. Kaikkonen
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-6339-0

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine